Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1999 1
2008 1
2009 1
2011 2
2012 1
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American Osteosarcoma Study) randomised clinical trial.
Hazewinkel AD, Lancia C, Anninga J, van de Sande M, Whelan J, Gelderblom H, Fiocco M. Hazewinkel AD, et al. BMJ Open. 2022 Mar 4;12(3):e053083. doi: 10.1136/bmjopen-2021-053083. BMJ Open. 2022. PMID: 35246418 Free PMC article. Clinical Trial.
OBJECTIVES: Investigating the effect of prognostic factors in a multistate framework on survival in a large population of patients with osteosarcoma. ...PARTICIPANTS: The subset of 1631 metastases-free patients from 1965 patients with high-grade resectable osteosarcoma, fr …
OBJECTIVES: Investigating the effect of prognostic factors in a multistate framework on survival in a large population of patients wi …
Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.
Im HJ, Kim TS, Park SY, Min HS, Kim JH, Kang HG, Park SE, Kwon MM, Yoon JH, Park HJ, Kim SK, Park BK. Im HJ, et al. Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):39-49. doi: 10.1007/s00259-011-1936-4. Epub 2011 Sep 28. Eur J Nucl Med Mol Imaging. 2012. PMID: 21953008 Clinical Trial.
Differences were also noted for all of these indices determined after one chemotherapy course. Furthermore, most of these indices determined after therapy as well as after one chemotherapy course had good sensitivity, specificity, positive predictive value an …
Differences were also noted for all of these indices determined after one chemotherapy course. Furthermore, most of these indices det …
Interferon-alpha/beta receptor as a prognostic marker in osteosarcoma.
Kubo T, Shimose S, Matsuo T, Fujimori J, Arihiro K, Ochi M. Kubo T, et al. J Bone Joint Surg Am. 2011 Mar 16;93(6):519-26. doi: 10.2106/JBJS.J.00198. J Bone Joint Surg Am. 2011. PMID: 21411701 Clinical Trial.
Multivariate analysis showed that interferon-alpha/beta receptor expression alone retained its power to predict an improved prognosis (p = 0.042). There were no significant variables after corrections for multiple comparisons. CONCLUSIONS: Interferon-alpha/beta rece …
Multivariate analysis showed that interferon-alpha/beta receptor expression alone retained its power to predict an improved progno …
Addition of Zoledronate to Chemotherapy in Patients with Osteosarcoma Treated with Limb-Sparing Surgery: A Phase III Clinical Trial.
Li S, Chen P, Pei Y, Zheng K, Wang W, Qiu E, Zhang X. Li S, et al. Med Sci Monit. 2019 Feb 23;25:1429-1438. doi: 10.12659/MSM.913236. Med Sci Monit. 2019. PMID: 30796194 Free PMC article. Clinical Trial.
In addition, in a standard chemotherapy regimen, patients enrolled in the zoledronate group also received 10 courses of 4 mg intravenous infusions of zoledronate (n=399). Limb-sparing surgery was performed by orthopedic surgeons (n=798). ...
In addition, in a standard chemotherapy regimen, patients enrolled in the zoledronate group also received 10 courses of 4 mg intraven …
Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma.
Imran H, Enders F, Krailo M, Sim F, Okuno S, Hawkins D, Neglia J, Randall RL, Womer R, Mascarenhas L, Arndt CA. Imran H, et al. J Bone Joint Surg Am. 2009 Mar 1;91(3):604-12. doi: 10.2106/JBJS.H.00449. J Bone Joint Surg Am. 2009. PMID: 19255220 Free PMC article.
A delay in the resumption of chemotherapy after definitive surgery for the treatment of osteosarcoma can decrease the overall dose intensity. The goal of this study was to assess the prognostic significance of the time to resumption of chemotherapy after definitive surgery …
A delay in the resumption of chemotherapy after definitive surgery for the treatment of osteosarcoma can decrease the overall dose intensity …
Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy.
Ongolo-Zogo P, Thiesse P, Sau J, Desuzinges C, Blay JY, Bonmartin A, Bochu M, Philip T. Ongolo-Zogo P, et al. Eur Radiol. 1999;9(5):907-14. doi: 10.1007/s003300050765. Eur Radiol. 1999. PMID: 10369989
At midpoint of the chemotherapy, these two imaging modalities failed in predicting final histological response. After the completion of the chemotherapy, these imaging modalities allowed the prediction of histological response with the same accuracy (91 %). In this …
At midpoint of the chemotherapy, these two imaging modalities failed in predicting final histological response. After the completion …